NBT Bank N.A. Purchases 38,634 Shares of Danaher Corporation $DHR

NBT Bank N.A. purchased a new stake in shares of Danaher Corporation (NYSE:DHR) during the third quarter, Holdings Channel reports. The fund purchased 38,634 shares of the conglomerate’s stock, valued at approximately $8,559,000.

A number of other hedge funds and other institutional investors have also modified their holdings of DHR. BlackRock Inc. bought a new stake in Danaher in the second quarter worth $10,492,520,000. Jupiter Topco LLC acquired a new position in Danaher during the second quarter worth $1,456,317,000. Generation Investment Management LLP acquired a new position in Danaher during the second quarter worth $1,287,949,000. Bank of America Corp DE bought a new position in Danaher during the second quarter valued at about $993,846,000. Finally, Legal & General Group Plc bought a new position in Danaher during the second quarter valued at about $801,056,000. Institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

NYSE DHR opened at $229.86 on Friday. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. The company has a fifty day simple moving average of $215.76 and a 200 day simple moving average of $197.12. The company has a market cap of $161.59 billion, a P/E ratio of 40.83, a P/E/G ratio of 2.95 and a beta of 0.76. Danaher Corporation has a 1 year low of $160.93 and a 1 year high of $242.80.

Danaher (NYSE:DHR) last posted its earnings results on Wednesday, October 21st. The conglomerate reported $2.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.92 by $0.19. The business had revenue of $6.55 billion for the quarter, compared to analyst estimates of $6.56 billion. Danaher had a net margin of 16.91% and a return on equity of 11.22%. Danaher’s revenue was up 8.3% compared to the same quarter last year. During the same period last year, the business posted $1.89 EPS. On average, sell-side analysts predict that Danaher Corporation will post 8.51 EPS for the current year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Wednesday, September 30th. Danaher’s dividend payout ratio is 28.42%.

More Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher reported third-quarter adjusted earnings of $2.11 per share, ahead of the $1.92 analyst consensus, while revenue increased 8.3% year over year to $6.55 billion. Biotechnology profitability and improving demand across several end markets supported the earnings beat. Danaher Beats Profit Estimates, Raises Outlook as Customer Demand Improves
• Positive Sentiment: Management raised its full-year 2026 adjusted EPS outlook to $8.57-$8.62, and biotechnology orders grew at a mid-teens rate. The company also highlighted margin expansion, improving customer demand, and artificial-intelligence capabilities that could support longer-term drug-discovery growth. Danaher: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Several analysts raised their price targets, including TD Cowen and JPMorgan to $270, Goldman Sachs to $275, and Stifel to $260. The upgrades reflect confidence in the earnings beat, improved execution, and the stronger profit outlook.
• Neutral Sentiment: New CEO Julie Montgomery emphasized the need to improve execution and innovation. Investors are watching whether management can convert the company’s AI and biotechnology investments into sustained growth. Danaher Posts First Earnings Under New CEO
• Negative Sentiment: Revenue was approximately in line with, or slightly below, estimates, while analysts cited tariff pressure and a cautious 2027 outlook. At roughly 41 times earnings, Danaher’s valuation leaves limited room for operational disappointment, contributing to the negative investor reaction despite the quarterly beat.

Wall Street Analyst Weigh In

DHR has been the subject of a number of analyst reports. Royal Bank Of Canada boosted their price target on Danaher from $215.00 to $250.00 and gave the stock an “outperform” rating in a research report on Monday, October 5th. Evercore reiterated an “outperform” rating and set a $230.00 price target on shares of Danaher in a research note on Monday, July 6th. Robert W. Baird increased their price objective on Danaher from $246.00 to $254.00 and gave the company an “outperform” rating in a report on Thursday. Guggenheim raised their price objective on Danaher from $200.00 to $250.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Finally, Citigroup boosted their target price on Danaher from $230.00 to $270.00 and gave the stock a “buy” rating in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $242.91.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.